✉news HealthMedicine first seen 6 d ago, last 6 d ago, peak #34
Prime Medicine Doses First Patient in Wilson Disease Trial
Original: Prime Medicine doses first patient in Wilson disease editing trial
Prime Medicine has dosed the first patient in a clinical trial of its gene editing therapy for Wilson disease, a rare genetic disorder that causes copper to accumulate in the body and damage the liver and brain. The milestone marks the start of patient treatment in the trial and is a key step forward for the company's prime editing technology.
Why now: The first patient dosing is a significant clinical milestone for a novel gene editing therapy, drawing attention from investors, patients and the biotech community.
Evidence
API: https://socialmediatrends-api.osmike.com/v1/trends/4444731